These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 26415829)

  • 1. Mannan-decorated thiolated Eudragit microspheres for targeting antigen presenting cells via nasal vaccination.
    Li HS; Singh B; Park TE; Hong ZS; Kang SK; Cho CS; Choi YJ
    Eur J Pharm Sci; 2015 Dec; 80():16-25. PubMed ID: 26415829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nasal immunization with mannan-decorated mucoadhesive HPMCP microspheres containing ApxIIA toxin induces protective immunity against challenge infection with Actinobacillus pleuropneumoiae in mice.
    Li HS; Shin MK; Singh B; Maharjan S; Park TE; Kang SK; Yoo HS; Hong ZS; Cho CS; Choi YJ
    J Control Release; 2016 Jul; 233():114-25. PubMed ID: 27189136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of thiolated eudragit microspheres as an oral vaccine delivery system to induce mucosal immunity against enterotoxigenic Escherichia coli in mice.
    Lee WJ; Cha S; Shin M; Jung M; Islam MA; Cho CS; Yoo HS
    Eur J Pharm Biopharm; 2012 May; 81(1):43-8. PubMed ID: 22306699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen.
    Slütter B; Bal S; Keijzer C; Mallants R; Hagenaars N; Que I; Kaijzel E; van Eden W; Augustijns P; Löwik C; Bouwstra J; Broere F; Jiskoot W
    Vaccine; 2010 Aug; 28(38):6282-91. PubMed ID: 20638455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally.
    Jaganathan KS; Vyas SP
    Vaccine; 2006 May; 24(19):4201-11. PubMed ID: 16446012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mannose-modified chitosan microspheres enhance OprF-OprI-mediated protection of mice against Pseudomonas aeruginosa infection via induction of mucosal immunity.
    Cui Z; Han D; Sun X; Zhang M; Feng X; Sun C; Gu J; Tong C; Lei L; Han W
    Appl Microbiol Biotechnol; 2015 Jan; 99(2):667-80. PubMed ID: 25381907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delivery of antigen to nasal-associated lymphoid tissue microfold cells through secretory IgA targeting local dendritic cells confers protective immunity.
    Rochereau N; Pavot V; Verrier B; Jospin F; Ensinas A; Genin C; Corthésy B; Paul S
    J Allergy Clin Immunol; 2016 Jan; 137(1):214-222.e2. PubMed ID: 26414879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.
    Bento D; Staats HF; Gonçalves T; Borges O
    Eur J Pharm Biopharm; 2015 Jun; 93():149-64. PubMed ID: 25818119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly(D,L-lactic-co-glycolic acid) microsphere delivery of adenovirus for vaccination.
    Wang D; Molavi O; Lutsiak ME; Elamanchili P; Kwon GS; Samuel J
    J Pharm Pharm Sci; 2007; 10(2):217-30. PubMed ID: 17706180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single nasal dose of CCL20 chemokine induces dendritic cell recruitment and enhances nontypable Haemophilus influenzae-specific immune responses in the nasal mucosa.
    Kodama S; Abe N; Hirano T; Suzuki M
    Acta Otolaryngol; 2011 Sep; 131(9):989-96. PubMed ID: 21534717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo induction of mucosal immune responses by intranasal administration of chitosan microspheres containing Bordetella bronchiseptica DNT.
    Kang ML; Kang SG; Jiang HL; Shin SW; Lee DY; Ahn JM; Rayamahji N; Park IK; Shin SJ; Cho CS; Yoo HS
    Eur J Pharm Biopharm; 2006 Jun; 63(2):215-20. PubMed ID: 16531027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eudragit® L100-coated mannosylated chitosan nanoparticles for oral protein vaccine delivery.
    Xu B; Zhang W; Chen Y; Xu Y; Wang B; Zong L
    Int J Biol Macromol; 2018 Jul; 113():534-542. PubMed ID: 29408613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivated influenza vaccine adjuvanted with bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion.
    Keijzer C; Haijema BJ; Meijerhof T; Voorn P; de Haan A; Leenhouts K; van Roosmalen ML; van Eden W; Broere F
    Vaccine; 2014 May; 32(24):2904-10. PubMed ID: 24598720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
    Gupta NK; Tomar P; Sharma V; Dixit VK
    Vaccine; 2011 Nov; 29(48):9026-37. PubMed ID: 21939718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines.
    Patel GB; Zhou H; Ponce A; Chen W
    Vaccine; 2007 Dec; 25(51):8622-36. PubMed ID: 17959279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combinatorial Approach of Antigen Delivery Using M Cell-Homing Peptide and Mucoadhesive Vehicle to Enhance the Efficacy of Oral Vaccine.
    Singh B; Maharjan S; Jiang T; Kang SK; Choi YJ; Cho CS
    Mol Pharm; 2015 Nov; 12(11):3816-28. PubMed ID: 26394158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of galactose-modified liposomes as a potent antigen presenting cell targeted carrier for intranasal immunization.
    Wang HW; Jiang PL; Lin SF; Lin HJ; Ou KL; Deng WP; Lee LW; Huang YY; Liang PH; Liu DZ
    Acta Biomater; 2013 Mar; 9(3):5681-8. PubMed ID: 23159567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of Local Secretory IgA and Multifunctional CD4⁺ T-helper Cells Following Intranasal Immunization with a H5N1 Whole Inactivated Influenza Virus Vaccine in BALB/c Mice.
    Trondsen M; Aqrawi LA; Zhou F; Pedersen G; Trieu MC; Zhou P; Cox RJ
    Scand J Immunol; 2015 May; 81(5):305-17. PubMed ID: 25737202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A protective vaccine delivery system for in vivo T cell stimulation using nanoengineered polymer hydrogel capsules.
    Sexton A; Whitney PG; Chong SF; Zelikin AN; Johnston AP; De Rose R; Brooks AG; Caruso F; Kent SJ
    ACS Nano; 2009 Nov; 3(11):3391-400. PubMed ID: 19824668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigen-adjuvant nanoconjugates for nasal vaccination: an improvement over the use of nanoparticles?
    Slütter B; Bal SM; Que I; Kaijzel E; Löwik C; Bouwstra J; Jiskoot W
    Mol Pharm; 2010 Dec; 7(6):2207-15. PubMed ID: 21043518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.